Key result
Andexanet alfa and ciraparantag are in development as reversal agents for Factor Xa inhibitors and have the potential to change the management of associated major hemorrhage.
Population
Patients with atrial fibrillation or venous thromboembolism taking oral Factor Xa inhibitors who experience…
Design
Review
Authors
Loading...
Should not yet alter reversal practices for Factor Xa inhibitor hemorrhage; leaves open the need for confirmatory trials before adoption.
Andexanet alfa and ciraparantag are emerging reversal agents that may change the management of major hemorrhage associated with Factor Xa inhibitors.
Milling et al. (2016) conducted a review in Factor Xa inhibitor-associated major hemorrhage. Andexanet alfa and ciraparantag was evaluated. Andexanet alfa and ciraparantag are in development as reversal agents for Factor Xa inhibitors and have the potential to change the management of associated major hemorrhage.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: